Generation of a human induced pluripotent stem cell line (SYSUTFi001-A) from infiltrating cytotoxic T cells in hepatocellular carcinoma (HCC)

Daopeng Yang; Xiangchao Ling; Furong Liu; Jinliang Duan; Fang Bai; Anbin Hu

doi:10.1016/j.scr.2022.102962

Generation of a human induced pluripotent stem cell line (SYSUTFi001-A) from infiltrating cytotoxic T cells in hepatocellular carcinoma (HCC)

Stem Cell Res. 2022 Dec:65:102962. doi: 10.1016/j.scr.2022.102962. Epub 2022 Nov 7.

Authors

Daopeng Yang¹, Xiangchao Ling¹, Furong Liu², Jinliang Duan¹, Fang Bai¹, Anbin Hu³

Affiliations

¹ Organ Transplant Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
² Department of Intensive Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
³ Organ Transplant Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Electronic address: anbinhu@163.com.

PMID: 36375283
DOI: 10.1016/j.scr.2022.102962

Abstract

In this study, we report a novel induced pluripotent stem cell (iPSC) line SYSUTFi001-A derived from cytotoxic T cells (CTLs) infiltrating in hepatocellular carcinoma (HCC), using an integrative Sendai virus vector. This pluripotent cell line shows a normal karyotype and can be redifferentiated to the rejuvenated CTLs targeted to HCC. The cell line SYSUTFi001-A can be further used to perform vitro and vivo anti-tumor assays and design future cell replacement therapies.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Hepatocellular* / therapy
Humans
Induced Pluripotent Stem Cells*
Liver Neoplasms* / therapy
T-Lymphocytes, Cytotoxic